<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628471</url>
  </required_header>
  <id_info>
    <org_study_id>UMAN-10-01</org_study_id>
    <nct_id>NCT01628471</nct_id>
  </id_info>
  <brief_title>MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uman Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MDEIE Ministry, Québec Government</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INRS-Institut Armand Frappier , Université du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uman Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is one of the most prevalent and lethal neoplasias in the world. Currently used&#xD;
      chemotherapy regimens have been disappointing in improving overall survival. Decitabine is a&#xD;
      S-phase pyrimidine analog that induces DNA hypomethylation. This drug is currently used to&#xD;
      treat Myelodysplastic Syndrome ( MDS) and has been studied for the treatment of leukemia.&#xD;
      Genistein, is a soy extracted non-toxic isoflavone and phytoestrogen, which has been shown to&#xD;
      inhibit activity of cell signaling pathways, such as those driven by tyrosine kinases.&#xD;
      Results from in vitro experiments unambiguously demonstrated that the combination of these&#xD;
      two compounds induces a synergistic reduction of the multiplication of lung, colon, breast&#xD;
      and leukemic cancer cells. Consequently, clinical evaluation of this drug combination is&#xD;
      warranted in Non Small Cell Lung Cancer ( NSCLC), and it is hypothezised that this new&#xD;
      regimen will safely improve overall tumor response rate and cancer progression free survival.&#xD;
&#xD;
      The proposed trial is a two part study: The phase I part is an open-label, dose-escalation&#xD;
      evaluation in subjects with advanced solid tumors who have failed standard therapies and for&#xD;
      whom no curative therapeutic option exists.&#xD;
&#xD;
      A cohort of three subjects will be treated per dose level. One cycle is 28 days. Five&#xD;
      different, increasing dose levels ranging from 60 mg/m2 to 500 mg/m2 of IV decitabine&#xD;
      combined with a fixed oral dose of 150 mg BID of genistein will be tested. The Maximum&#xD;
      Tolerated Dose (MTD) will be determined based on the occurrence of Dose Limiting Toxicities&#xD;
      (DLTs).&#xD;
&#xD;
      In the phase IIa part of the study, only Stage IIIb and IV advanced NSCLC patients will be&#xD;
      treated at the recommended decitabine MTD dose combined with genistein. Safety and&#xD;
      preliminary efficacy will be assessed. It is expected that a maximum sample of 46 patients&#xD;
      will be enrolled in this trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 day treatment cycle for MTD assessment; 4-6 cycles to be administered</time_frame>
    <description>MTD determination will based on the incidence of reported adverse events (including dose-limiting toxicities) and abnormal laboratory test results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the drug plasma concentrations of decitabine and genistein.</measure>
    <time_frame>Up to 6 , 28 day treatment cycles</time_frame>
    <description>Plasma drug levels will be used to obtain preliminary PK profile. Up to 11 blood samples to be obtained from each enrolled patient, over several cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary clinical efficacy assessment</measure>
    <time_frame>Up to 6, 28 day treatment cycles</time_frame>
    <description>Preliminary efficacy of the investigational regimen will include the assessment of Overall Response Rate ( ORR) and Progression Free Survival(PFS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Decitabine + genistein single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>decitabine injectable, by infusion, 5 ascending doses (60 to 500 mg/m2) genisteine capsules, 3 x 50 mg capsules twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine in combination with genistein</intervention_name>
    <description>decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine</description>
    <arm_group_label>Decitabine + genistein single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written Informed Consent.&#xD;
&#xD;
          -  Males or females.&#xD;
&#xD;
          -  18-75 years.&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-estrogen dependent advanced solid&#xD;
             malignancy who has failed standard therapies and/or for which no curative therapeutic&#xD;
             option exists (phase I) or ;&#xD;
&#xD;
          -  Histologically or cytologically confirmed NSCLC of stage IIIb or IV (phase IIa) that&#xD;
             has failed or is ineligible to standard therapies.&#xD;
&#xD;
          -  One or more tumor lesions measurable by RECIST criteria&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  ECOG performance of 2 or less.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior decitabine or genistein therapy.&#xD;
&#xD;
          -  Received cytotoxic agent, hormonal therapy, radiation therapy, or other targeted&#xD;
             cancer therapies or investigational agent within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Patients with confirmed estrogen receptor-positive cancers, or patients with a primary&#xD;
             breast or endometrial cancer for which phenotyping analysis has not been performed.&#xD;
&#xD;
          -  Presence of uncontrolled brain metastases or leptomeningeal disease.&#xD;
&#xD;
          -  Uncontrolled cardiovascular disorders, including symptomatic heart failure, unstable&#xD;
             angina and cardiac arrhythmias.&#xD;
&#xD;
          -  Inadequate baseline organ function as shown by following laboratory values :&#xD;
&#xD;
               -  Hemoglobin &lt; 90 g/L&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1,500 /microliter&#xD;
&#xD;
               -  Platelet count &lt; 100,000 /microliter&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 ULN&#xD;
&#xD;
               -  AST and ALT &gt; 2.5 ULN&#xD;
&#xD;
               -  Creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  To be dependent of oxygen treatment.&#xD;
&#xD;
          -  Active infections requiring antibiotics.&#xD;
&#xD;
          -  Pregnancy or breastfeeding. All women of child-bearing potential must have a negative&#xD;
             pregnancy test prior to first receiving protocol therapy.&#xD;
&#xD;
          -  Known allergic reactions to soy derivatives or deoxycytidine derivatives.&#xD;
&#xD;
          -  Active alcohol or drug abuse.&#xD;
&#xD;
          -  Any co-morbid condition that in the judgment of the investigator renders the subject&#xD;
             at high risk of treatment complication or reduces the probability of assessing&#xD;
             clinical effect.&#xD;
&#xD;
          -  Other malignancies diagnosed within the last 5 years with the exception of Basal Cell&#xD;
             Carcinoma of the skin.&#xD;
&#xD;
          -  Gastrointestinal disorders or abnormalities that may interfere with the absorption of&#xD;
             genistein.&#xD;
&#xD;
          -  Patients unable to comply with the study protocol and follow-up schedule for any&#xD;
             psychological, familial, sociological or geographical reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Normand Blais, MD, FRCP(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Notre Dame du CHUM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Notre Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.umanpharma.com</url>
    <description>Study sponsor</description>
  </link>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I b : advanced solid malignancy</keyword>
  <keyword>Phase II a: stage III b or IV, Non Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

